切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2024, Vol. 13 ›› Issue (06) : 831 -835. doi: 10.3877/cma.j.issn.2095-3232.2024059

临床研究

基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用
刘敏思1, 李荣1, 李媚1,()   
  1. 1.510630 广州,中山大学附属第三医院广东省肝脏病研究重点实验室
  • 收稿日期:2024-07-19 出版日期:2024-12-10
  • 通信作者: 李媚
  • 基金资助:
    广东省基础与应用基础研究自然科学基金面上项目(2024A1515011662)广州市校(院)联合资助项目-基础与应用基础研究项目(2023A03J0727)

Diagnostic value of GGT-Plt ratio-based model for HBV-related hepatocellular carcinoma

Minsi Liu1, Rong Li1, Mei Li1,()   

  1. 1.Guangdong Provincial Key Laboratory of Liver Disease Research,the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,China
  • Received:2024-07-19 Published:2024-12-10
  • Corresponding author: Mei Li
引用本文:

刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.

Minsi Liu, Rong Li, Mei Li. Diagnostic value of GGT-Plt ratio-based model for HBV-related hepatocellular carcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 831-835.

目的

探讨GGT与Plt比值(GPR)联合中性粒细胞与淋巴细胞比值(NLR)、Plt与淋巴细胞比值(PLR)以及淋巴细胞与单核细胞比值(LMR)在HBV相关肝细胞癌(HBV-HCC)中的诊断价值。

方法

回顾性分析2012年1月至2018年9月中山大学附属第三医院收治的1119例慢性乙型病毒性肝炎(乙肝)、乙肝后肝硬化、HBV-HCC患者临床资料。其中非肝癌组784例,男648例,女136例;年龄18~82岁,中位年龄43岁;肝癌组335例,男303例,女32例;年龄21~83岁,中位年龄54岁。肝癌诊断单因素分析采用Mann-Whitney U检验或χ2检验,单因素分析中P<0.1的指标经共线性诊断,方差膨胀因子<5的指标进入Logistic多因素回归可得独立影响因子,用于建立HBV-HCC的Logistic回归模型,其诊断价值采用ROC的曲线下面积(AUC)进行分析。

结果

Logistic多因素回归显示,男性、PLR、GPR和年龄是HBV-HCC的独立危险因素(OR=2.876,1.004,1.151,1.070;P<0.05),基于以上因素构建的Logistic回归模型的AUC为0.782(敏感度0.740,特异度0.719)。该模型与AFP联合诊断的AUC为0.855,可提高AFP(AUC 0.778)的诊断效能(Z=-5.400,P<0.05)。

结论

GPR联合PLR的Logistic 回归模型对早期HBV-HCC诊断有一定的临床价值,其与AFP联合可提高AFP的诊断效能。

Objective

To evaluate the diagnostic value of GGT-Plt ratio (GPR) combined with neutrophil-lymphocyte ratio (NLR),Plt-lymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR) for HBV-related hepatocellular carcinoma (HBV-HCC).

Methods

Clinical data of 1119 patients with chronic hepatitis B,post-hepatitis B cirrhosis and HBV-HCC admitted to the Third Affiliated Hospital of Sun Yat-sen University from January 2012 to September 2018 were retrospectively analyzed. Among them,784 patients were assigned in the non-HCC group,648 male and 136 female,aged 18-82 years,with a median age of 43 years. 335 cases were included in the HCC group,303 male and 32 female,aged 21-83 years,with a median age of 54 years. Univariate analysis of HCC diagnosis was conducted by Mann-Whitney U test or Chi-square test. In univariate analysis,the parameters with P<0.1 were used for collinear diagnosis,and the parameters with variance inflation factor of <5 were included into multivariate Logistic regression analysis to obtain the independent influencing factors,which were used to establish Logistic regression model for HBV-HCC. The diagnostic value was evaluated by the area under the ROC curve (AUC).

Results

Multivariate Logistic regression analysis showed that male,PLR,GPR and age were the independent risk factors for HBV-HCC (OR=2.876,1.004,1.151,1.070; P<0.05). The AUC of Logistic regression model based on the above factors was 0.782 with a sensitivity of 0.740 and a specificity of 0.719. The AUC of this model combined with AFP was 0.855,which enhanced the diagnostic efficiency of AFP (AUC=0.778)(Z=-5.400, P<0.05).

Conclusions

The Logistic regression model based on GPR combined with PLR has certain clinical value for early diagnosis of HBV-HCC. This model in combination with AFP can improve the diagnostic efficiency of AFP.

表1 HBV-HCC相关因素的单因素分析
表2 HBV-HCC相关因素的Logistic多因素回归分析
图1 AFP、Logistic模型以及两者联合诊断HBV-HCC的ROC曲线
表3 AFP、Logistic模型以及两者联合诊断HBV-HCC的ROC曲线比较
[1]
郑荣寿,陈茹,韩冰峰,等. 2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
[2]
Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[3]
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2024年版)[J]. 中华外科杂志,2024,62(6):477-503.
[4]
Matsas S,Aguiar PN Jr,Del Giglio A. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis[J]. J Gastrointest Oncol,2024,15(1):33-51.
[5]
Muangto T,Maireang K,Poomtavorn Y,et al. Study on preoperative neutrophil/lymphocyte (NLR) and platelet/lymphocyte ratio (PLR) as a predictive factor in endometrial cancer[J]. Asian Pac J Cancer Prev,2022,23(10):3317-3322.
[6]
Cao W,Yu H,Zhu S,et al. Clinical significance of preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in the prognosis of resected early-stage patients with non-small cell lung cancer: a meta-analysis[J]. Cancer Med,2023,12(6):7065-7076.
[7]
Wang L,Li X,Liu M,et al. Association between monocyte-tolymphocyte ratio and prostate cancer in the U.S. population: a population-based study[J]. Front Cell Dev Biol,2024,12:1372731.
[8]
Zhang H,Li Y,Liu G,et al. Expression analysis of lymphocyte subsets and lymphocyte-to-monocyte ratio: reveling immunosuppression and chronic inflammation in breast cancer[J]. J Cancer Res Clin Oncol,2024,150(1):28.
[9]
Lemoine M,Shimakawa Y,Nayagam S,et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa[J]. Gut,2016,65(8):1369-1376.
[10]
Park YE,Kim BK,Park JY,et al. Gamma-glutamyl transpeptidase-toplatelet ratio is an independent predictor of hepatitis B virus-related liver cancer[J]. J Gastroenterol Hepatol,2017,32(6):1221-1229.
[11]
王金涛,韩博强,安东均,等. 术前血清γ-谷氨酰转肽酶与血小板比值预测乙型肝炎病毒相关性肝细胞癌患者预后的预测模型构建[J]. 中国普外基础与临床杂志,2023,30(4):450-455.
[12]
Dai T,Deng M,Ye L,et al. Prognostic value of combined preoperative gamma-glutamyl transpeptidase to platelet ratio and fibrinogen in patients with HBV-related hepatocellular carcinoma after hepatectomy[J]. Am J Transl Res,2020,12(6):2984-2997.
[13]
Ke MY,Zhang M,Su Q,et al. Gamma-glutamyl transpeptidase to platelet ratio predicts short-term outcomes in hepatocellular carcinoma patients undergoing minor liver resection[J]. J Surg Res,2018,231:403-410.
[14]
中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志,2022,30(12):1309-1331.
[15]
中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J/OL]. 中华肝脏外科手术学电子杂志,2024,13(4):407-449.
[16]
Kramvis A,Chang KM,Dandri M,et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook[J].Nat Rev Gastroenterol Hepatol,2022,19(11):727-745.
[17]
Li S,Lu Z,Wu S,et al. The dynamic role of platelets in cancer progression and their therapeutic implications[J]. Nat Rev Cancer,2024,24(1):72-87.
[18]
刘双池,庞青,谈燚. 血小板在肝细胞癌发生和转移中的研究进展[J/OL]. 中华普通外科学文献(电子版),2021,15(1):66-69.
[19]
Tesfamariam B. Involvement of platelets in tumor cell metastasis[J].Pharmacol Ther,2016,157:112-119.
[20]
Lavergne M,Janus-Bell E,Schaff M,et al. Platelet integrins in tumor metastasis: do they represent a therapeutic target?[J]. Cancers,2017,9(10):133.
[21]
Li DZ,Guo J,Song QK,et al. Prognostic prediction of the plateletto-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis[J]. Transl Cancer Res,2022,11(11):4037-4050.
[22]
Wang D,Bai N,Hu X,et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC[J].PeerJ,2019,7:e7132.
[23]
Hofbauer SL,Stangl KI,de Martino M,et al. Pretherapeutic gammaglutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma[J]. Br J Cancer,2014,111(8):1526-1531.
[24]
Wen YF,Yang XZ,Zeng LS,et al. Prognostic impact of pretherapeutic gamma-glutamyltransferase on patients with nasopharyngeal carcinoma[J]. PLoS One,2017,12(2):e0172345.
[25]
Yang F,Zhang S,Yang H,et al. Prognostic significance of gammaglutamyltransferase in patients with resectable esophageal squamous cell carcinoma[J]. Dis Esophagus,2015,28(5):496-504.
[26]
Luo D,Li H,Hu J,et al. Development and validation of nomograms based on gamma-glutamyl transpeptidase to platelet ratio for hepatocellular carcinoma patients reveal novel prognostic value and the ratio is negatively correlated with P38MAPK expression[J]. Front Oncol,2020,10:548744.
[27]
黄琴,彭晓明,梅丽萍,等. PIVKA-Ⅱ、GGT、GPR、GLR、PLR对乙型肝炎相关性原发性肝癌的诊断价值研究[J]. 中西医结合肝病杂志,2024,34(4):327-330.
[1] 中国医师协会肝癌专业委员会. 肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)[J]. 中华普通外科学文献(电子版), 2024, 18(05): 313-324.
[2] 汤宏涛, 何坤. 中晚期肝细胞癌介入治疗的进展及前景[J]. 中华普通外科学文献(电子版), 2024, 18(04): 305-308.
[3] 丁丁, 杨云川, 马翔, 马中正, 霍俊一, 周磊. 术前C-反应蛋白-白蛋白-淋巴细胞比值在肝细胞癌预后中的价值评估[J]. 中华普通外科学文献(电子版), 2024, 18(04): 261-265.
[4] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[5] 陆朝阳, 金也, 孙备. 腹腔镜解剖性肝切除的发展[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 363-366.
[6] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[7] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[8] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[9] 王向前, 李清峰, 陈磊, 丘文丹, 姚志成, 李熠, 吴荣焕. 姜黄素抑制肝细胞癌索拉非尼耐药作用及其调控机制[J]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 729-735.
[10] 龚财芳, 赵俊宇, 游川. 围手术期肠内营养在肝癌肝切除患者中有效性及安全性的Meta分析[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 551-556.
[11] 张杰, 田广磊, 陈雄. 基于生物信息学分析探讨肝癌BRD4与预后关系及其ceRNA调控网络构建[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 568-576.
[12] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 407-449.
[13] 钟造茂, 罗文超, 蔡满航, 陈显育, 钟跃思. 肝癌肝切除术后肝衰竭的危险因素分析及列线图模型构建[J]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 289-295.
[14] 曾谣, 谢琴, 陈显育, 王平根, 毛玲秋, 何丹玲, 杜飞, 郑希彦, 何函樨. CDC42EP2基因与肝癌预后、免疫细胞浸润关系及其对细胞迁移侵袭的影响[J]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 363-369.
[15] 杨兴业, 彭旭云, 曾倩, 梁伟铖, 肖翠翠, 郑俊, 姚嘉. LMO7通过靶向铁死亡促进肝细胞癌生长[J]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 370-376.
阅读次数
全文


摘要